公开(公告)号：US12128132B2

公开(公告)日：2024-10-29

申请号：US18391243

申请日：2023-12-20

申请人： MedinCell S.A.

发明人： Anthony Rech ,  Christophe Roberge ,  Eran Harary

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K47/20 ,  A61K47/34 ,  A61P25/18

CPC分类号： A61K9/0024 ,  A61K31/519 ,  A61K47/20 ,  A61K47/34 ,  A61P25/18

摘要： The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

公开(公告)号：US20240350544A1

公开(公告)日：2024-10-24

申请号：US18640982

申请日：2024-04-19

申请人： Takeda Pharmaceutical Company Limited

发明人： Michael Curley ,  Ertan Eryilmaz ,  Shawn Jennings ,  LeeAnn Talarico ,  Taylor Hickman ,  Christina Sheau Fen Wong ,  Kathryn Fraser ,  Haiqing Wang ,  Alessandra Piersigilli

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464416 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48 ,  C07K2317/565

摘要： This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

公开(公告)号：US12121591B2

公开(公告)日：2024-10-22

申请号：US18392458

申请日：2023-12-21

申请人： NanoVation Therapeutics Inc.

发明人： Deaglan Arnold ,  Nagavenkata Durga Prasad Atmuri ,  Fariba Saadati ,  Huy Tran ,  Marco A. Ciufolini

IPC分类号： A61K47/69 ,  A61K9/51 ,  A61K47/20 ,  C07C323/12 ,  C07C323/25 ,  C07D205/04 ,  C07D317/28

CPC分类号： A61K47/6929 ,  A61K9/5123 ,  A61K47/20 ,  C07C323/12 ,  C07C323/25 ,  C07D205/04 ,  C07D317/28 ,  C07B2200/05

摘要： Provided herein is an ionizable, cationic amino lipid or a pharmaceutically acceptable salt thereof. The ionizable, cationic amino lipid has:



a protonatable amino head group;
two lipophilic chains, wherein the protonatable amino head group has a central carbon atom to which each of the two lipophilic chains are directly bonded;
at least one of the two lipophilic chains has a structure of Formula C:










wherein E is an ester in either orientation. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid.

公开(公告)号：US20240342249A1

公开(公告)日：2024-10-17

申请号：US18640676

申请日：2024-04-19

申请人： Xeris Pharmaceuticals, Inc.

发明人： Steven PRESTRELSKI ,  Michael SANDOVAL ,  Martin DONOVAN

IPC分类号： A61K38/26 ,  A61K9/00 ,  A61K9/08 ,  A61K38/00 ,  A61K47/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61M5/142 ,  A61M5/32

CPC分类号： A61K38/26 ,  A61K9/0019 ,  A61K9/08 ,  A61K38/00 ,  A61K47/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/186 ,  A61K47/20 ,  A61K47/26 ,  A61M5/142 ,  A61M5/32

摘要： Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

公开(公告)号：US12116366B2

公开(公告)日：2024-10-15

申请号：US18610041

申请日：2024-03-19

申请人： Avicenna Biosciences, Inc.

发明人： Thomas Maxwell Kaiser

IPC分类号： C07D471/04 ,  A61K9/00 ,  A61K9/08 ,  A61K31/437 ,  A61K47/20 ,  A61K47/38

CPC分类号： C07D471/04 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/437 ,  A61K47/20 ,  A61K47/38

摘要： This invention provides rho-associated protein kinase (ROCK) inhibiting compounds for therapeutic applications as described further herein.

公开(公告)号：US20240325393A1

公开(公告)日：2024-10-03

申请号：US18041844

申请日：2021-07-07

申请人： VYNE THERAPEUTICS INC.

发明人： Russell ELLIOTT ,  Yohan HAZOT ,  Gareth WINCKLE ,  Ariel MARGULIS

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K9/06 ,  A61K31/137 ,  A61K31/197 ,  A61K31/506 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34 ,  A61K47/36 ,  A61K47/44

CPC分类号： A61K31/519 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/137 ,  A61K31/197 ,  A61K31/506 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34 ,  A61K47/36 ,  A61K47/44

摘要： The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, vitiligo and eczema.

公开(公告)号：US20240317869A1

公开(公告)日：2024-09-26

申请号：US18656957

申请日：2024-05-07

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA ,  HOFFMANN-LA ROCHE INC.

发明人： Toshiyuki MORICHIKA ,  Daisuke KAMEOKA ,  Yoshimi IMAEDA ,  Terutoshi MAEDA ,  Oliver Boris STAUCH

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  C07K1/14

CPC分类号： C07K16/2866 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26 ,  C07K1/14 ,  A61K9/0019 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.

公开(公告)号：US12090226B2

公开(公告)日：2024-09-17

申请号：US18588687

申请日：2024-02-27

申请人： Cristcot LLC

发明人： Jennifer J. Davagian ,  Raj Devarajan

IPC分类号： A61K9/02 ,  A61K9/00 ,  A61K31/573 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61M31/00

CPC分类号： A61K9/025 ,  A61K9/0031 ,  A61K9/02 ,  A61K31/573 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61M31/007 ,  A61M2210/1064 ,  A61M2210/1067

摘要： The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

公开(公告)号：US20240293350A1

公开(公告)日：2024-09-05

申请号：US18258857

申请日：2021-12-22

申请人： EGE UNIVERSITESI ,  MEFAR ILAC SAN. A.S.

发明人： Kambez HAJIPOURAN BENAM ,  Ozlem YESIL ,  Tuncay GOKSEL ,  Mine OZYAZICI ,  Mesut ARICI ,  Aysu YURDASIPER ,  Ozlem GOKSEL

IPC分类号： A61K31/245 ,  A61K9/00 ,  A61K47/12 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26

CPC分类号： A61K31/245 ,  A61K9/0078 ,  A61K47/12 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26

摘要： The development of innovative inhalation formulations and preparation methods are provided to be used in the prophylaxis of COVID-19-related mortality from a broad-spectrum serine protease inhibitor NM, which has a potent anti-viral and anti-inflammatory potential. A drug for the infection treatment of SARS-COV-2, Influenza A, Influenza B and NL63 viruses includes the drug substance Nafamostat mesylate, which is a serine protease inhibitor in its inhalation form.

公开(公告)号：US12076345B2

公开(公告)日：2024-09-03

申请号：US17827077

申请日：2022-05-27

申请人： Avotres, Inc.

发明人： Hong Jiang

IPC分类号： A61K35/15 ,  A61K31/10 ,  A61K35/17 ,  A61K38/17 ,  A61K38/38 ,  A61K47/20 ,  A61K47/42 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/0784 ,  G01N33/50

CPC分类号： A61K35/17 ,  A61K31/10 ,  A61K35/15 ,  A61K38/1709 ,  A61K38/38 ,  A61K47/20 ,  A61K47/42 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/70539 ,  C12N5/0637 ,  C12N5/0639 ,  G01N33/505 ,  C12N2501/22 ,  C12N2501/2304

摘要： The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).